Navigation Links
Neurocrine Announces Work Force Restructuring
Date:12/13/2007

SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today staff reductions of approximately 130 employees at its San Diego campus, as a part of its restructuring program to prioritize its research and development programs and associated costs and expenses after the setback on indiplon. Following these reductions, Neurocrine will have approximately 120 employees.

"It is with great disappointment that we have to make this difficult decision that will have such an effect on so many of our employees and their families. We are greatly saddened to move in this direction after our employees have continually demonstrated only the highest level of dedication and commitment. However, in order to meet our goals on other high priority programs, we have to refocus our resources as quickly as possible. I want to sincerely thank the departing employees for their tremendous efforts and wish them great success in the future," said Gary Lyons President & CEO. "We will maintain our focus on determining the path forward with indiplon after interactions with the FDA, and our efforts on GnRH, as we move expeditiously toward partnering this program. We will also continue with focused research and development efforts aimed at treating diseases of the central nervous and endocrine systems. We intend to continue to conservatively manage our cash resources and review collaborative alternatives to fund the advancement of our pipeline."

The Company is preparing a formal meeting request to the FDA to discuss the 2007 Approvable Letter. We have notified FDA that we would be submitting this formal request.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, diabetes, irritable bowel syndrome, and CNS related disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties relating to Neurocrine's indiplon program that could cause actual results to differ materially from those indicated in the forward-looking statements. Specifically, the risks and uncertainties the Company faces with respect to its indiplon program include, but are not limited to; risk that the Company will not be able to address issues and or requests set forth in the December 12, 2007 indiplon capsule action letter from the FDA in a timely manner if at all; risk that the Company will not be able to address issues and or requests set forth in the December 12, 2007 indiplon capsule action letter from the FDA in a manner acceptable to the FDA if at all; the risk that FDA may reject any future indiplon regulatory filings or find them incomplete or insufficient; and risk that indiplon approval and subsequent commercialization may be significantly or indefinitely delayed. In addition, the Company faces risks and uncertainties with respect to the Company's GnRH receptor antagonist program including risk that the GnRH receptor antagonist clinical candidates will not proceed to later stage clinical trials; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; risk that the Company will be unable to raise additional funding required to complete development of all of its product candidates; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2006 and the Company's report on Form 10-Q for the quarter ended September 30, 2007. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
3. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
4. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
5. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
8. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
9. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LAKES, N.J. , Jan. 18, 2017 BD (Becton, ... technology company, announced today that it will host a live webcast ... at 1 p.m. (ET). The webcast can be ... be available for replay through Tuesday, January 31, 2017. ... About BD BD ...
(Date:1/18/2017)... 2017 Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced that Dr. ... of Applied BioMath, will present at the next ... Meeting on Thursday January 19, 2017 at the ... MA.   Dr. Burke,s talk "Quantitative Modeling and Simulation ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse Labs ... Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables / ... planned for further growth in 2017. Extractable & Leachable evaluations have become increasingly ...
(Date:1/18/2017)... KING OF PRUSSIA, PA (PRWEB) , ... January ... ... to disrupt clinical operations again at the CHI SCOPE Summit for Clinical Ops ... and AstraZeneca in engaging panel discussions to examine vital clinical research issues such ...
Breaking Biology Technology:
(Date:1/6/2017)... 5, 2017  SomaLogic announced today that it ... established by iCarbonX, the China ... "Global Digital Health Ecosystem that can define each ... individual,s biological, behavioral and psychological data, the Internet ... companies, SomaLogic will provide proteomics data and applications ...
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
Breaking Biology News(10 mins):